Rantum Capital acquires high-tech medical technology company Stockert
- Stockert is a global market leader and “hidden champion” from Freiburg, Germany
- Stockert’s technology is market-leading in minimally invasive treatment (ablation) of cardiac arrhythmias
- Management team intends to continue successful growth course
Rantum Private Equity Fund II has acquired 100% of the shares in Stockert GmbH (“Stockert”). The company was sold by industrial holding Metechon AG, whose shareholders were looking for a succession solution for Stockert due to age reasons.
Stockert is the global market leader for cardiac ablation systems, a high-growth niche market with high technological and regulatory entry barriers. The company from the “MedTech Valley” in South Baden/Freiburg can look back on a long and successful history of innovation in the field of electrophysiology. The high-frequency ablation generator including irrigation pump from Stockert is the “gold standard” for the minimally invasive treatment of cardiac arrhythmias and the most frequently used system worldwide.
Klaus Welte, Managing Director of Stockert, comments: “We are delighted to have found a partner in Rantum who shares our vision and will invest together with us in the development of the next generations of technology to drive Stockert’s growth. With the help of Rantum’s capital and broad network, we can leverage our strong product and technology platform to develop new products, application areas, and customer segments.”
“With its innovative strength and technological expertise, Stockert is a typical hidden champion in the German SME segment. The company offers the perfect platform in terms of technology and regulation to grow both organically and inorganically. We want to give Stockert’s management new freedom and support them in actively developing the company and setting it up to prosper in the future,” adds Gilles Djordjevic, Managing Director at Rantum Capital.
